Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)

--News Direct--

In a market where noise often overshadows substance, Nuvectis Pharma (NASDAQ: NVCT)* is delivering a signal that’s hard to ignore — sustained insider buying by one of the company’s most informed and sophisticated investors.

On June 20, 2025, Charles Mosseri-Marlio, a well-known biotech investor and former pharmaceutical executive, filed a Form 4 disclosing the purchase of 33,442 additional shares of NVCT at $8.05 per share. The $270,000 transaction adds to his already significant position, which now totals just under 3 million shares through Emerald Hill Capital. This marks the third major insider buy by Mosseri-Marlio in 2025 alone — with previous purchases in February and May at lower price points. The pattern is clear: this is not opportunistic trading, it’s strategic accumulation.

What makes this even more notable is Mosseri-Marlio’s background. He previously held a leadership role at Flamel Technologies (now Avadel Pharmaceuticals), where he helped secure development deals with top-tier partners like Pfizer and GlaxoSmithKline. He’s not only familiar with drug pipelines — he’s built them. Combined with a track record in institutional asset management, his buying carries more weight than your average insider move. He’s not chasing momentum — he’s betting on execution.

And there’s plenty in the Nuvectis pipeline to justify that bet. The company is currently advancing two first-in-class oncology candidates — NXP800 and NXP900 — both of which are in clinical trials targeting cancers with high unmet need. NXP800 is in Phase 1b development for ARID1a-mutated, platinum-resistant ovarian cancer — a devastating subtype with few effective treatments. The drug has already earned Fast Track and Orphan Drug designations from the FDA, streamlining its development and signaling strong regulatory support. Data from this trial is expected later this year, and could be a key near-term catalyst.

NXP900, meanwhile, is designed to address drug resistance in advanced cancers, including non-small cell lung cancer. By inhibiting SRC and YES1 kinases, NXP900 targets the very mechanisms that allow tumors to escape the effects of EGFR and ALK inhibitors — two of the most common first-line treatments in NSCLC. After completing its Phase 1a study, the company is now preparing to launch combination trials that could demonstrate its potential to restore drug sensitivity in resistant tumors.

Despite these promising programs, Nuvectis remains deeply undervalued relative to peers. The company’s market cap sits around $150 million — a fraction of other precision oncology players at similar stages. Nuvalent (NASDAQ: NUVL), for example, trades north of $6 billion with programs focused on the same indication space. Summit Therapeutics (NASDAQ: SMMT), which also targets drug-resistant cancers, surged to nearly $15 billion in valuation earlier this year following a pivotal trial result. Nuvectis isn’t there yet — but if it delivers on either of its two clinical programs, it may not be far behind.

Importantly, the company is financially stable. Nuvectis raised $15.5 million in early 2025, bringing its total cash reserves to nearly $30 million as of March. That provides runway into 2027, giving it ample time to reach key milestones without returning to the market for funding. It also means less dilution risk — a crucial factor for investors in early-stage biotech.

This backdrop of strong insider ownership, solid financials, and high-impact drug development is what makes the Mosseri-Marlio buying spree so compelling. He’s not the only one with conviction either — CEO Ron Bentsur and other insiders continue to hold sizable stakes and have not sold a single share. Bentsur, notably, has a track record of taking biotech companies through FDA approval and delivering real value to shareholders.

Year-to-date, NVCT is up significantly but it’s still relatively under the radar. That may not last long. With clinical data expected soon, strong internal alignment, and one of the most experienced insider buyers in the sector continuing to build his position, Nuvectis Pharma may be one of the few small-cap biotechs positioned for a breakout in the second half of 2025.

-

News Highlights from Nuvectis

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

-

* Paid Advertisement Disclaimer & Disclosure: This content is not financial or investment advice, and the authors are not licensed brokers, dealers or advisors. This article was Published by the. Wall Street Wire™ platform and network, which is operated by Arx Advisory Ltd (the “Operators”). The Operators receive a monthly cash subscription fee from Nuvectis Pharma (NVCT) via bank transfer for services relating to promotional content and news distributions on various media and social channels. The Operators may received additional cash fees for monitoring, data or IR/advisory services on top of that. For specific details and full disclosures on the exact cash amounts paid for the Wall Street Wire subscription and the start date of such services, please refer to our full disclosure document: https://redditwire.com/terms

Contact Details

News Coverage

media.globalmarkets@gmail.com

View source version on newsdirect.com: https://newsdirect.com/news/smart-money-is-quietly-loading-up-on-this-160m-oncology-stock-is-nuvectis-pharma-the-next-breakout-biotech-nasdaq-nvct-638840400

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.